DD285718A5 - Verfahren zur herstellung eines oralen therapeutischen systems fuer carbamazepin mit systemischer wirkung - Google Patents

Verfahren zur herstellung eines oralen therapeutischen systems fuer carbamazepin mit systemischer wirkung Download PDF

Info

Publication number: DD285718A5
Authority: DD; German Democratic Republic
Prior art keywords: core; carbamazepine; shell; water; therapeutic system
Prior art date: 1986-08-07

Application number

DD87305733A

Other languages

German (de)

English (en)

Inventor

Satish Ch Khanna

Theresa Ruettimann

Original Assignee

��`��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-07

Filing date

1987-08-05

Publication date

1991-01-03

1987-08-05 Application filed by ��`��@��k�� filed Critical ��`��@��k��

1991-01-03 Publication of DD285718A5 publication Critical patent/DD285718A5/de

Links

230000001225 therapeutic effect Effects 0.000 title claims abstract description 42
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 title claims abstract description 39
229960000623 carbamazepine Drugs 0.000 title claims abstract description 36
238000000034 method Methods 0.000 title claims description 19
230000009885 systemic effect Effects 0.000 title claims description 4
238000004519 manufacturing process Methods 0.000 title description 8
230000008961 swelling Effects 0.000 claims abstract description 29
239000004480 active ingredient Substances 0.000 claims abstract description 25
239000003795 chemical substances by application Substances 0.000 claims abstract description 23
239000000084 colloidal system Substances 0.000 claims abstract description 19
239000013078 crystal Substances 0.000 claims abstract description 19
230000001681 protective effect Effects 0.000 claims abstract description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
210000001124 body fluid Anatomy 0.000 claims abstract description 13
239000010839 body fluid Substances 0.000 claims abstract description 13
230000001939 inductive effect Effects 0.000 claims abstract description 8
229920001577 copolymer Polymers 0.000 claims description 17
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 17
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 17
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 17
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 14
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
229920002678 cellulose Polymers 0.000 claims description 10
239000011780 sodium chloride Substances 0.000 claims description 10
239000013543 active substance Substances 0.000 claims description 9
239000001913 cellulose Substances 0.000 claims description 9
239000000463 material Substances 0.000 claims description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
229930195725 Mannitol Natural products 0.000 claims description 7
239000008103 glucose Substances 0.000 claims description 7
235000001727 glucose Nutrition 0.000 claims description 7
239000000594 mannitol Substances 0.000 claims description 7
235000010355 mannitol Nutrition 0.000 claims description 7
239000012528 membrane Substances 0.000 claims description 7
229920000609 methyl cellulose Polymers 0.000 claims description 6
239000001923 methylcellulose Substances 0.000 claims description 6
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
239000001103 potassium chloride Substances 0.000 claims description 5
235000011164 potassium chloride Nutrition 0.000 claims description 5
235000015424 sodium Nutrition 0.000 claims description 5
229920003086 cellulose ether Polymers 0.000 claims description 4
239000000470 constituent Substances 0.000 claims description 4
229920001519 homopolymer Polymers 0.000 claims description 4
150000002500 ions Chemical class 0.000 claims description 4
239000000178 monomer Substances 0.000 claims description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
239000011248 coating agent Substances 0.000 claims description 3
238000000576 coating method Methods 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
238000006116 polymerization reaction Methods 0.000 claims description 3
239000002195 soluble material Substances 0.000 claims description 2
239000000126 substance Substances 0.000 abstract description 8
206010015037 epilepsy Diseases 0.000 abstract description 3
230000001773 anti-convulsant effect Effects 0.000 abstract description 2
239000001961 anticonvulsive agent Substances 0.000 abstract description 2
229960003965 antiepileptics Drugs 0.000 abstract description 2
239000011162 core material Substances 0.000 abstract 3
230000002920 convulsive effect Effects 0.000 abstract 1
229920002301 cellulose acetate Polymers 0.000 description 21
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
230000003204 osmotic effect Effects 0.000 description 11
239000002245 particle Substances 0.000 description 11
-1 Alkyl glycidyl ethers Chemical class 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 9
239000008187 granular material Substances 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 9
229940090016 tegretol Drugs 0.000 description 9
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 8
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
239000011734 sodium Substances 0.000 description 7
229910052708 sodium Inorganic materials 0.000 description 7
239000004354 Hydroxyethyl cellulose Substances 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
235000010980 cellulose Nutrition 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
235000010981 methylcellulose Nutrition 0.000 description 6
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
235000019333 sodium laurylsulphate Nutrition 0.000 description 6
239000001856 Ethyl cellulose Substances 0.000 description 5
229920003083 Kollidon® VA64 Polymers 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
235000019325 ethyl cellulose Nutrition 0.000 description 5
229920001249 ethyl cellulose Polymers 0.000 description 5
238000002156 mixing Methods 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000000243 solution Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000004683 dihydrates Chemical group 0.000 description 4
238000005755 formation reaction Methods 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000005553 drilling Methods 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000013081 microcrystal Substances 0.000 description 3
238000005192 partition Methods 0.000 description 3
229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
238000001238 wet grinding Methods 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000701 coagulant Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000001035 drying Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000011389 fruit/vegetable juice Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical class CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000035515 penetration Effects 0.000 description 2
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
229920002689 polyvinyl acetate Polymers 0.000 description 2
239000011118 polyvinyl acetate Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229950004959 sorbitan oleate Drugs 0.000 description 2
229950003429 sorbitan palmitate Drugs 0.000 description 2
229950011392 sorbitan stearate Drugs 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
229960004129 sorbitan tristearate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
XUXJHBAJZQREDB-UHFFFAOYSA-N 2-methylbutanamide Chemical compound CCC(C)C(N)=O XUXJHBAJZQREDB-UHFFFAOYSA-N 0.000 description 1
MCDQYEUDJIBGFS-UHFFFAOYSA-N 2-octadecoxyethyl hydrogen sulfate Chemical compound CCCCCCCCCCCCCCCCCCOCCOS(O)(=O)=O MCDQYEUDJIBGFS-UHFFFAOYSA-N 0.000 description 1
SWPLMYYBIPGCRH-UHFFFAOYSA-N 2-tetradecoxyethyl hydrogen sulfate Chemical compound CCCCCCCCCCCCCCOCCOS(O)(=O)=O SWPLMYYBIPGCRH-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical class CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920008347 Cellulose acetate propionate Polymers 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
239000004147 Sorbitan trioleate Chemical class 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
HVWGGPRWKSHASF-UHFFFAOYSA-N Sulfuric acid, monooctadecyl ester Chemical compound CCCCCCCCCCCCCCCCCCOS(O)(=O)=O HVWGGPRWKSHASF-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
VEHZBMGMMPZMRJ-UHFFFAOYSA-N acetic acid;2-(diethylamino)acetic acid Chemical compound CC(O)=O.CCN(CC)CC(O)=O VEHZBMGMMPZMRJ-UHFFFAOYSA-N 0.000 description 1
YMNMXQILQOXZPB-UHFFFAOYSA-N acetic acid;4-methylbenzenesulfonic acid Chemical compound CC(O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 YMNMXQILQOXZPB-UHFFFAOYSA-N 0.000 description 1
WOOJRPBCEMEHLS-UHFFFAOYSA-N acetic acid;butane-1-sulfonic acid Chemical compound CC(O)=O.CCCCS(O)(=O)=O WOOJRPBCEMEHLS-UHFFFAOYSA-N 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
IIOPVJIGEATDBS-UHFFFAOYSA-N acetic acid;dodecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCC(O)=O IIOPVJIGEATDBS-UHFFFAOYSA-N 0.000 description 1
CBICCXFXCXELAR-UHFFFAOYSA-N acetic acid;ethyl hydrogen carbonate Chemical compound CC(O)=O.CCOC(O)=O CBICCXFXCXELAR-UHFFFAOYSA-N 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
150000008051 alkyl sulfates Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
HLKZFSVWBQSKKH-UHFFFAOYSA-N but-3-enoic acid;1-ethenylpyrrolidin-2-one Chemical compound OC(=O)CC=C.C=CN1CCCC1=O HLKZFSVWBQSKKH-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009837 dry grinding Methods 0.000 description 1
YPZOCKHNHHMXDI-ZWGPAORLSA-N ethyl (2S)-2-[[4-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl]amino]-4-methylpentanoate Chemical compound CCOC(=O)[C@H](CC(C)C)NC1CCC(CC1)n1cc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc12 YPZOCKHNHHMXDI-ZWGPAORLSA-N 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
SSILHZFTFWOUJR-UHFFFAOYSA-N hexadecane-1-sulfonic acid Chemical compound CCCCCCCCCCCCCCCCS(O)(=O)=O SSILHZFTFWOUJR-UHFFFAOYSA-N 0.000 description 1
LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
229940127022 high-dose drug Drugs 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Inorganic materials [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
NOQOJKIYCAQVMC-UHFFFAOYSA-L magnesium;2-dodecoxyethyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOCCOS([O-])(=O)=O.CCCCCCCCCCCCOCCOS([O-])(=O)=O NOQOJKIYCAQVMC-UHFFFAOYSA-L 0.000 description 1
ANGQSOHCVRDFPI-UHFFFAOYSA-L magnesium;dodecane-1-sulfonate Chemical compound [Mg+2].CCCCCCCCCCCCS([O-])(=O)=O.CCCCCCCCCCCCS([O-])(=O)=O ANGQSOHCVRDFPI-UHFFFAOYSA-L 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
238000000465 moulding Methods 0.000 description 1
PNLUGRYDUHRLOF-UHFFFAOYSA-N n-ethenyl-n-methylacetamide Chemical compound C=CN(C)C(C)=O PNLUGRYDUHRLOF-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
CACRRXGTWZXOAU-UHFFFAOYSA-N octadecane-1-sulfonic acid Chemical compound CCCCCCCCCCCCCCCCCCS(O)(=O)=O CACRRXGTWZXOAU-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
XIPFMBOWZXULIA-UHFFFAOYSA-N pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000004080 punching Methods 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
229960005055 sodium ascorbate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 1
229950005425 sodium myristyl sulfate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
239000001589 sorbitan tristearate Chemical class 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 description 1
MYOWBHNETUSQPA-UHFFFAOYSA-N tetradecane-1-sulfonic acid Chemical compound CCCCCCCCCCCCCCS(O)(=O)=O MYOWBHNETUSQPA-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

DD87305733A 1986-08-07 1987-08-05 Verfahren zur herstellung eines oralen therapeutischen systems fuer carbamazepin mit systemischer wirkung DD285718A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH3172/86A CH668187A5 (de)	1986-08-07	1986-08-07	Therapeutisches system mit systemischer wirkung.

Publications (1)

Publication Number	Publication Date
DD285718A5 true DD285718A5 (de)	1991-01-03

Family

ID=4250176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87305733A DD285718A5 (de)	1986-08-07	1987-08-05	Verfahren zur herstellung eines oralen therapeutischen systems fuer carbamazepin mit systemischer wirkung

Country Status (30)

Country	Link
US (1)	US4857336A (fr)
JP (1)	JP2592460B2 (fr)
KR (1)	KR950006219B1 (fr)
AT (1)	AT397344B (fr)
AU (1)	AU597403B2 (fr)
BE (1)	BE1000235A3 (fr)
CA (1)	CA1302267C (fr)
CH (1)	CH668187A5 (fr)
DD (1)	DD285718A5 (fr)
DE (1)	DE3725824C2 (fr)
DK (1)	DK175497B1 (fr)
ES (1)	ES2007100A6 (fr)
FI (1)	FI86143C (fr)
FR (1)	FR2602425B1 (fr)
GB (1)	GB2193632B (fr)
GR (1)	GR871234B (fr)
HK (1)	HK33793A (fr)
HU (1)	HU206978B (fr)
IE (1)	IE59718B1 (fr)
IL (1)	IL83386A (fr)
IT (1)	IT1215618B (fr)
LU (1)	LU86966A1 (fr)
MY (1)	MY100767A (fr)
NL (1)	NL194780C (fr)
NO (1)	NO173726C (fr)
NZ (1)	NZ221347A (fr)
PH (1)	PH25090A (fr)
PT (1)	PT85489B (fr)
SE (1)	SE502590C2 (fr)
ZA (1)	ZA875804B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0277092B1 (fr) *	1987-01-14	1992-01-29	Ciba-Geigy Ag	Système thérapeutique pour médicaments peu solubles
IL86211A (en) *	1987-05-04	1992-03-29	Ciba Geigy Ag	Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
US4824675A (en) *	1987-07-13	1989-04-25	Alza Corporation	Dispenser with movable matrix comprising a plurality of tiny pills
NZ226179A (en) *	1987-09-24	1991-04-26	Merck & Co Inc	Controlled porosity osmotic pump for sustained release of pharmaceutical agents
US5019397A (en) *	1988-04-21	1991-05-28	Alza Corporation	Aqueous emulsion for pharmaceutical dosage form
JP2893191B2 (ja) *	1988-11-08	1999-05-17	武田薬品工業株式会社	放出制御性マトリックス剤
US5108756A (en) *	1989-01-12	1992-04-28	Pfizer Inc.	Dispensing devices powered by lyotropic liquid crystals
US5030452A (en) *	1989-01-12	1991-07-09	Pfizer Inc.	Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
EP0408496A3 (en) *	1989-07-12	1992-07-01	Ciba-Geigy Ag	Solid dosage form for pharmaceutical substances
US5035897A (en) *	1989-09-05	1991-07-30	Alza Corporation	Dosage form for delivering soluble or insoluble drugs
US5284662A (en) *	1990-10-01	1994-02-08	Ciba-Geigy Corp.	Oral osmotic system for slightly soluble active agents
RU2111663C1 (ru) *	1991-01-16	1998-05-27	Фмк Корпорейшн	Твердая сыпучая композиция носителя для активного вещества в твердой дозированной вододиспергируемой форме, способ ее получения и твердая дозированная форма
US5643591A (en) *	1991-01-16	1997-07-01	Fmc Corporation	Solid dosage forms
US5326570A (en) *	1991-07-23	1994-07-05	Pharmavene, Inc.	Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
DE69425453T2 (de) *	1993-04-23	2001-04-12	Novartis Ag, Basel	Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US6676967B1 (en)	1993-09-20	2004-01-13	Kos Pharmaceuticals, Inc.	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en)	1993-09-20	2000-06-27	Bova; David J.	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en)	1993-09-20	2004-11-16	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en)	1993-09-20	2004-06-08	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en)	1993-09-20	2000-10-10	Bova; David J.	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
ZA953078B (en) *	1994-04-28	1996-01-05	Alza Corp	Effective therapy for epilepsies
US20040191314A1 (en) *	1994-04-28	2004-09-30	Frank Jao	Antiepileptic dosage form and process for protecting antiepileptic drug
DE4423078B4 (de) *	1994-07-01	2005-01-13	Awd.Pharma Gmbh & Co. Kg	Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
US5800832A (en) *	1996-10-18	1998-09-01	Virotex Corporation	Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US5980942A (en) *	1997-01-23	1999-11-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en)	1997-01-23	2001-10-02	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) *	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en)	1997-02-14	2002-02-21	Burkhard Schlutermann	Oxacarbazepine film-coated tablets
JP2001517625A (ja)	1997-09-25	2001-10-09	バイエル・アクチエンゲゼルシヤフト	活性成分放出制御薬物製剤
US6099859A (en) *	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
PT1079813E (pt) *	1998-04-29	2005-05-31	Virotex Corp	Dispositivo transportador farmaceutico adequado para entrega de compostos farmaceuticos as superficies mucosas
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
CA2434169C (fr) *	2001-01-12	2011-03-15	Sun Pharmaceutical Industries Limited	Systeme de liberation espacee de medicaments
IN190699B (fr) *	2001-02-02	2003-08-16	Sun Pharmaceutical Ind Ltd
CA2443632C (fr) *	2001-04-10	2011-05-03	Sun Pharmaceutical Industries Limited	Composition a liberation par impulsion reglee dans le temps
RU2189225C1 (ru) *	2001-09-14	2002-09-20	Нестерук Владимир Викторович	Лекарственное средство на основе карбамазепина
US20030175346A1 (en) *	2002-02-01	2003-09-18	Anne Billotte	Osmotic delivery system
US20030161882A1 (en) *	2002-02-01	2003-08-28	Waterman Kenneth C.	Osmotic delivery system
US6572889B1 (en)	2002-03-07	2003-06-03	Noveon Ip Holdings Corp.	Controlled release solid dosage carbamazepine formulations
WO2003075830A2 (fr) *	2002-03-14	2003-09-18	Sun Pharmaceutical Industries Limited	Système de délivrance contrôlée de médicament par voie orale
US9060941B2 (en) *	2002-09-20	2015-06-23	Actavis, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) *	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en)	2002-09-20	2011-06-14	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7842791B2 (en) *	2002-12-19	2010-11-30	Nancy Jean Britten	Dispersible pharmaceutical compositions
US20060210633A1 (en) *	2003-04-03	2006-09-21	Sun Pharmaceutical Industries Limited	Programmed drug delivery system
RU2240798C1 (ru) *	2003-06-25	2004-11-27	Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин"	Фармацевтическая композиция, обладающая противосудорожным и психотропным действием, и способ ее получения
EP1690540A1 (fr) *	2005-02-15	2006-08-16	Neuro3D	Composition comprenant l'ocapéridone
JP2008539240A (ja) *	2005-04-25	2008-11-13	テバファーマシュ−ティカルズユーエスエー，インコーポレイテッド	持続放出性処方物
US20070071819A1 (en) *	2005-05-30	2007-03-29	Kesarwani Amit K	Multiple unit modified release compositions of carbamazepine and process for their preparation
DK2054031T3 (en)	2006-07-21	2016-05-17	Biodelivery Sciences Int Inc	Transmucosal delivery devices with improved uptake
US20090143362A1 (en) *	2007-12-04	2009-06-04	Barabde Umesh Vinayakrao	Carbamazepine formulations
EP2231169B1 (fr) *	2007-12-06	2016-05-04	Bend Research, Inc.	Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension
WO2009073216A1 (fr)	2007-12-06	2009-06-11	Bend Research, Inc.	Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
AU2012296346A1 (en)	2011-08-18	2014-04-03	Biodelivery Sciences International, Inc.	Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US9901539B2 (en)	2011-12-21	2018-02-27	Biodelivery Sciences International, Inc.	Transmucosal drug delivery devices for use in chronic pain relief

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4111202A (en) *	1976-11-22	1978-09-05	Alza Corporation	Osmotic system for the controlled and delivery of agent over time
US4431641A (en) *	1980-10-17	1984-02-14	Ciba-Geigy Corporation	Pharmaceutical compositions having antiepileptic and antineuralgic action
US4327725A (en) *	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
CH649080A5 (de) *	1981-04-16	1985-04-30	Ciba Geigy Ag	5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4553973A (en) *	1982-07-12	1985-11-19	Alza Corporation	Process for preparing osmotic device
GB2150830B (en) *	1983-12-05	1987-08-19	Alza Corp	Drug dispenser
US4716031A (en) *	1984-03-21	1987-12-29	Alza Corporation	Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4685918A (en) *	1985-02-01	1987-08-11	Merck & Co., Inc.	Lipid osmotic pump

1986
- 1986-08-07 CH CH3172/86A patent/CH668187A5/de not_active IP Right Cessation
1987
- 1987-07-24 GB GB8717643A patent/GB2193632B/en not_active Expired - Lifetime
- 1987-07-29 US US07/079,055 patent/US4857336A/en not_active Ceased
- 1987-07-30 IL IL83386A patent/IL83386A/xx not_active IP Right Cessation
- 1987-08-03 SE SE8703034A patent/SE502590C2/sv not_active IP Right Cessation
- 1987-08-04 DE DE3725824A patent/DE3725824C2/de not_active Expired - Lifetime
- 1987-08-04 GR GR871234A patent/GR871234B/el unknown
- 1987-08-05 FR FR878711131A patent/FR2602425B1/fr not_active Expired - Lifetime
- 1987-08-05 NZ NZ221347A patent/NZ221347A/xx unknown
- 1987-08-05 FI FI873409A patent/FI86143C/fi not_active IP Right Cessation
- 1987-08-05 IT IT8748270A patent/IT1215618B/it active
- 1987-08-05 PH PH35631A patent/PH25090A/en unknown
- 1987-08-05 DD DD87305733A patent/DD285718A5/de not_active IP Right Cessation
- 1987-08-05 LU LU86966A patent/LU86966A1/fr unknown
- 1987-08-05 PT PT85489A patent/PT85489B/pt unknown
- 1987-08-05 CA CA000543746A patent/CA1302267C/fr not_active Expired - Lifetime
- 1987-08-06 BE BE8700868A patent/BE1000235A3/fr not_active IP Right Cessation
- 1987-08-06 MY MYPI87001227A patent/MY100767A/en unknown
- 1987-08-06 NO NO873298A patent/NO173726C/no not_active IP Right Cessation
- 1987-08-06 JP JP62195407A patent/JP2592460B2/ja not_active Expired - Lifetime
- 1987-08-06 NL NL8701857A patent/NL194780C/nl not_active IP Right Cessation
- 1987-08-06 AU AU76617/87A patent/AU597403B2/en not_active Expired
- 1987-08-06 DK DK198704107A patent/DK175497B1/da not_active IP Right Cessation
- 1987-08-06 AT AT0199387A patent/AT397344B/de not_active IP Right Cessation
- 1987-08-06 IE IE211087A patent/IE59718B1/en not_active IP Right Cessation
- 1987-08-06 HU HU873590A patent/HU206978B/hu unknown
- 1987-08-06 ZA ZA875804A patent/ZA875804B/xx unknown
- 1987-08-07 KR KR1019870008652A patent/KR950006219B1/ko not_active Expired - Lifetime
- 1987-08-07 ES ES8702339A patent/ES2007100A6/es not_active Expired
1993
- 1993-04-08 HK HK337/93A patent/HK33793A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATA199387A (de)	1993-08-15
NO173726B (no)	1993-10-18
FI873409A7 (fi)	1988-02-08
KR950006219B1 (ko)	1995-06-12
DK410787D0 (da)	1987-08-06
NL8701857A (nl)	1988-03-01
FI86143B (fi)	1992-04-15
SE8703034D0 (sv)	1987-08-03
GB2193632A (en)	1988-02-17
NO873298D0 (no)	1987-08-06
FI86143C (fi)	1992-07-27
NO873298L (no)	1988-02-08
IE872110L (en)	1988-02-07
IT1215618B (it)	1990-02-22
LU86966A1 (fr)	1989-03-08
IL83386A (en)	1992-01-15
PH25090A (en)	1991-02-19
CH668187A5 (de)	1988-12-15
DK175497B1 (da)	2004-11-15
KR880002511A (ko)	1988-05-09
AT397344B (de)	1994-03-25
PT85489A (en)	1987-09-01
GR871234B (en)	1987-12-08
FR2602425A1 (fr)	1988-02-12
IL83386A0 (en)	1987-12-31
HU206978B (en)	1993-03-01
DE3725824C2 (de)	1998-12-17
HK33793A (en)	1993-04-16
ZA875804B (en)	1988-02-08
FR2602425B1 (fr)	1990-09-14
BE1000235A3 (fr)	1988-09-20
MY100767A (en)	1991-02-14
AU7661787A (en)	1988-02-11
FI873409A0 (fi)	1987-08-05
NL194780B (nl)	2002-11-01
SE502590C2 (sv)	1995-11-20
JP2592460B2 (ja)	1997-03-19
JPS6344525A (ja)	1988-02-25
NZ221347A (en)	1989-12-21
PT85489B (pt)	1990-06-29
GB2193632B (en)	1990-04-25
GB8717643D0 (en)	1987-09-03
US4857336A (en)	1989-08-15
CA1302267C (fr)	1992-06-02
NL194780C (nl)	2003-03-04
IE59718B1 (en)	1994-03-23
HUT44930A (en)	1988-05-30
ES2007100A6 (es)	1989-06-01
NO173726C (no)	1994-01-26
AU597403B2 (en)	1990-05-31
DE3725824A1 (de)	1988-02-11
IT8748270A0 (it)	1987-08-05
DK410787A (da)	1988-02-08
SE8703034L (sv)	1988-02-08

Legal Events

Date	Code	Title	Description
2000-03-02	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
AT397344B (de)	1994-03-25	Verfahren zur herstellung eines oralen therapeutischen systems für carbamazepin
EP0277092B1 (fr)	1992-01-29	Système thérapeutique pour médicaments peu solubles
DE60038698T2 (de)	2009-05-07	Hydrogel-gesteuerte dosierungsform
EP1024793B1 (fr)	2002-01-16	Systeme osmotique de liberation de medicament
EP0339506B1 (fr)	1992-05-13	Système osmotique oral avec adhésion améliorée de la membrane au noyau
DE69629797T2 (de)	2004-07-15	Matrix zur gesteuerten freisetzung von arzneistoffen
DE69909801T2 (de)	2004-06-03	Oral verabreichtes system zur zeitlich und räumlich gesteuerten arzneistoffabgabe
DE69213729T2 (de)	1997-01-30	Dosierungsform enthaltend einen polymer mit verschiedenen molekularen gewichte
USRE34990E (en)	1995-07-04	Oral therapeutic system having systemic action
DE69011878T2 (de)	1994-12-15	Von Hydrogel angetriebene Verabreichungsvorrichtung.
DE69427466T2 (de)	2002-04-25	Bisacodyl dosierungsform
DE60019334T2 (de)	2005-09-08	Antivirale arznei
EP0720473A1 (fr)	1996-07-10	Pellets de budesonide a liberation controlee et leur procede de preparation
DE69709101T2 (de)	2002-04-25	Therapie mittels gleichförmiger arzneistoffverabreichung
DD248057A5 (de)	1987-07-29	Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-/imino/2-(2-methoxyethoxy)ethyliden/-oxy/-9s)-erythromycin und verfahren zu ihrer herstellung
EP2155172A2 (fr)	2010-02-24	Système de rétention gastrique renfermant un corps d'alginate
DE60309832T2 (de)	2007-10-11	Osmotisches verabreichungssystem
DE3909520A1 (de)	1989-10-05	Feste, schnell zerfallende darreichungsformen
DE60034142T2 (de)	2007-12-13	Darreichungsform mit einer inneren Membran, einer Verdrängungszusammentzung und einer äußeren semipermeablen Membran
EP2959887B1 (fr)	2018-11-14	Médicament pour le traitement des vertiges de diverses origines
DE3790355C2 (de)	1998-08-20	Verfahren zur Herstellung magensalzsäureneutralisierender pharmazeutischer Präparate mit großer säurebindender Kapazität, verzögerter Wirkungsdauer und vergrößerter Bioverfügbarkeit
EP0271438A2 (fr)	1988-06-15	Système osmotique oral pour le metoprolol avec une composition particulière
SI8810221A (sl)	1995-12-31	Postopek za pripravo oralnega terapevtskega sistema
DE202004009564U1 (de)	2005-01-13	Pharmazeutische Zusammensetzung mit nachhaltiger Freisetzung
DE202004009563U1 (de)	2004-11-11	Pharmazeutische Zusammensetzung mit nachhaltiger Freisetzung